Liver transplantation in HIV-positive patients

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 39-46

  Norris, Suzanne ^a   Houlihan, Diarmaid ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cirrhosis; End stage liver disease; Hepatitis; Highly active antiretroviral therapy; HIV infection; Liver transplantation

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; GUANOSINE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RAPAMYCIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TENOFOVIR;

CLINICAL TRIAL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DONOR SELECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FATTY LIVER; GRAFT INFECTION; GRAFT REJECTION; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL ETHICS; MIXED INFECTION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS HEPATITIS; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 49149092289     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.39     Document Type: Review

References (75)

1. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324, 757 (2002).
2. Freedberg KA, Scharfstein JA, Seage GR 3rd et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 279, 130-136 (1998).
3. Sterne JA, Hernan MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366, 378-384 (2005).
4. Walensky RP, Paltiel AD, Losina E et al. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194, 11-19 (2006).
5. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann. Intern. Med. 145, 397-406 (2006).
6. Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 350, 1425-1431 (1997).
7. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infict. Dis. 32, 492-497 (2001).
8. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch. Intern. Med. 166, 1632-1641 (2006).
9. Colin JF, Cazals-Hatem D, Loriot Ma et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepaology 29, 1306-1310 (1999).
10. Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int. J. Epidemiol. 34, 121-130 (2005).
11. Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV + patients. Transplantation 49, 354-358 (1990).
12. Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH Jr. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev. Infect. Dis. 13, 537-547 (1991).
13. Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin. Infect. Dis. 19, 854-859 (1994).
14. Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotropic liver transplantation in patients with haemophilia. Gut 42, 744-749 (1998).
15. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a cross sectional analysis of the US adult AIDS Clinical Trials Group. Clin. Infect. Dis. 34, 831-837 (2002).
16. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C infection in the United States, 1998 through 1994. N. Engl. J. Med. 341, 556-562 (1994).
17. Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 364, 83-94 (2004).
18. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. 192, 992-1002 (2005).
19. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19, 593-601 (2005).
20. Di Martino V, Rufat P. Boyer N et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34, 1193-1199 (2001).
21. Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patient in the era of highly active antiretroviral therapy. AIDS 15, 291-292 (2001).
22. Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J. Infect. Dis. 188, 1412-1420 (2003).
23. Prachalias AA, Pozniak A, Taylor C et al. Liver transplantation in adults coinfected with HIV. Transplantation 72, 1684-1688 (2001).
24. Radecke K, Fruhauf NR, Miller M et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver. Int. 25, 101-108 (2005).
25. Norris S, Taylor C, Muiesan P et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl. 10, 1271-1278 (2004).
26. Miro JM, Montejo M, Rufi G et al. Liver transplantation in patients with HIV infection: a reality in 2004. Enferm. Infec. Microbiol. Clin. 22, 529-538 (2004).
27. Vogel M, Voigt E, Schafer N et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort. Liver Transpl. 11, 1515-1521 (2005).
28. Wojcik K, Vogel M, Voigt E et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 21, 1363-1365 (2007).
29. Fung J, Eghtesad B, Patel-Tom K, De Vera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl. 10(Suppl. 2), S39-S53 (2004).
30. de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am. J. Transplant. 6, 2983-2993 (2006).
31. Devlin J, O'Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut 45(Suppl. VI), V 11-V 22 (1999).
32. Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet 354, 1636-1639 (1999).
33. Stock PG, Roland ME, Carlson L et al. Kidney and liver transalantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 76, 370-375 (2003).
34. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 75, 425-429 (2003).
35. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection. HIV Med. 6, 149-153 (2005).
36. Miro JM, Torre-Cisneros J, Moreno A et al. GESIDA/GESITRA/-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain, 2005. Enferm. Infecc. Microbiol. Clin. 23, 353-362 (2005).
37. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin. Liver. Dis. 26, 273-284 (2006).
38. Roland ME, Stock PG. Comprehensive guidelines translate research findings into clinical policy for HIV-infected transplant candidates and recipients. Enferm. Infecc. Microbiol. Clin. 23, 331-334 (2005).
39. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterolog. 124, 91-96 (2003).
40. Ragni M, Eghtesad B, Schlesinger KW et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end stage liver disease. Liver. Transpl. 11, 1425-1430 (2005).
41. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41, 779-789 (2005).
42. Lapoile E, Vona G, Canioni D et al. Factors participating in severe HCV-related liver disease in HIV/HCV coinfection. J. Hepatol. 1, 609A (2002).
43. Chariot P, Drogou I, de Lacroix-Szmania I et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol. 30, 156-160 (1999).
44. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann. Intern. Med. 115, 283-284 (1991).
45. Arribas JR, Ibanez C, Ruiz-Antoran B et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 12, 1722-1724 (1998).
46. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283, 74-80 (2000).
47. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving neviripine-containing anti-retroviral therapy. AIDS 15, 1261-1268 (2001).
48. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and one non-nucleoside reverse transcriptase inhibitor. AIDS 14(Suppl. 4) (2000).
49. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33, 1358-1364 (2001).
50. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28, 805-809 (1998).
51. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-4503A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug. Metab. Dispos. 20, 753-761 (1992).
52. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano, T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268, 6077-6080 (1993).
53. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 68, 307-309 (1999).
54. Jain AK, Venkataramanan R, Shapiro R et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Tanspl. 9, 841-845 (2002).
55. Tseng A, Nguyen ME, Cardella C, Humar A, Conly J. Probable interaction between efavirenz and cyclosporine. AIDS 16, 505-506 (2002).
56. Antonini M, Ettorre GM, Vennarecci G et al. Anti-retrovirals and immunosuppressive drug interactions in a HIV-positive patient after liver transplantation. Hepatogastroenterology 51, 646-648 (2004).
57. Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J. Acquir. Immune Defic. Syndr. 21, 362-370 (1999).
58. Jain AK, Venkataramanan R, Fridell JA et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 8, 838-840 (2002).
59. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavarin in HIV/HCV coinfection. Lancet 357, 280-281 (2001).
60. Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART fbilowing liver transplantation in an HIV-infected recipient. Liver Tanspl. 10, 699-702 (2004).
61. Bartz SR, Hohenwalter E, Hu MK, Rich DH, Malkovsky M. Inhibition of human immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc. Natl. Acad. Sci. USA 92, 5381-5385 (1995).
62. Calabrese LH, Lederman MM, Spritzler J et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation. J. Acquir. Immune Defic. Syndr. 29, 356-362 (2002).
63. McComsey GA, Whalen CC, Mawhorter SD et al. Placebo-controlled trial of prednisolone in advanced HIV-1 infection. AIDS 15, 321-327 (2001).
64. Coull JJ, Turner D, Melby T, Betts MR, Lanier R. Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J. Acquir. Immune Defic. Syndr. 26, 423-434 (2001).
65. Duclos-Vallee JC, Vittecoq D, Teicher E et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J. Hepatol. 42, 34 1-349 (2005).
66. Rafecas A, Rufi G, Figueras J et al. Liver transplantation without steroid induction in HIV-infected patients. Liver Transpl. 10, 1320-1323 (2004).
67. Moreno S, Fortun J, Quereda C et al. Liver transplantation in HIV-infected recipients. Liver Transpl. 11, 76-81 (2005).
68. Gonzalez Alonso I, Barcena R, Blesa C et al. Liver transplantation in a patient coinfected with human immunodeficiency virus and hepatitis C virus. Transplant. Proc. 35, 1846-1847 (2003).
69. Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV/ HBV International Panel. AIDS 19, 221-240 (2005).
70. Halpern SD, Asch DA, Shaked A, Stock PG, Blumberg E. Determinants of transplant surgeons' willingness to provide organs to patients infected with HBV, HCV or HIV Am. J. Transplant. 5, 1319-1325 (2005).
71. Samuel D, Dulcos-Vallee JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J. Hepatol. 39, 3-6 (2003).
72. Goldberg D, Johnston J, Cameron S et al. Risk of HIV transmission from patients to surgeons in the era of post-exposure prophylaxis. J. Hosp. Infect. 44, 99-105 (2000).
73. Health and Public Policy Committee, American College of Physcians, Infectious Diseases Society of America. The acquired immunodeficiency syndrome (AIDS) and infection with the human immunodeficiency virus (HIV). Ann. Intern. Med. 108, 460-469 (1988).
74. Council on Ethical and Judicial Affairs. Ethical issues involved in the growing AIDS crisis. JAMA 259, 1360-1361 (1988).
75. Miro JM, Laguno M, Moreno A, Rimola A; Hospital Clinic OLT In HIVWorking Group. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J. Hepatol. 44, S140-S145 (2006).